跳至主要内容
临床试验/NL-OMON55123
NL-OMON55123招募中不适用

HD-med: A longitudinal, observational study to assess medication use, medication efficacy and the role of pharmacogenetics in Huntington*s Disease. - HD-med: Pharmacogenetics in Huntington*s Disease

eids Universitair Medisch Centrum0 个研究点目标入组 391 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
391

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - A capacitated individual, aged >= 18 years.
  • - Genetically confirmed CAG-repeat expansion of >= 36 in the Huntingtin gene.
  • - Either about to start with prescribed medication related to HD or already
  • using one or more HD related drugs. HD-related drugs are drugs considered to
  • treat symptoms that either are related to manifest HD or are prescribed in
  • pre-motor manifest or prodromal HD stage for symptoms that may be attributed to
  • - Sufficient knowledge of the Dutch language to understand the subject
  • information letter and sign the IC.

排除标准

  • Any medical condition, in the view of the investigator, which might endanger
  • subject*s safety and/or satisfactory participation in the study.

研究者

相似试验

HD-med: A longitudinal, observational study to... | 临床试验